TY  - JOUR
A1  - Ejrnaes, Mette
A1  - Herrath, Matthias G. von
A1  - Christen, Urs
T1  - Cure of chronic viral infection and virus-induced type 1 diabetes by neutralizing antibodies
T2  - Clinical & developmental immunology
N2  - The use of neutralizing antibodies is one of the most successful methods to interfere with receptor-ligand interactions in vivo. In particular blockade of soluble inflammatory mediators or their corresponding cellular receptors was proven an effective way to regulate inflammation and/or prevent its negative consequences. However, one problem that comes along with an effective neutralization of inflammatory mediators is the general systemic immunomodulatory effect. It is therefore important to design a treatment regimen in a way to strike at the right place and at the right time in order to achieve maximal effects with minimal duration of immunosuppression or hyperactivation. In this review we reflect on two examples of how short time administration of such neutralizing antibodies can block two distinct inflammatory consequences of viral infection. First, we review recent findings that blockade of IL-10/IL-10R interaction can resolve chronic viral infection and second, we reflect on how neutralization of the chemokine CXCL10 can abrogate virus-induced type 1 diabetes.
KW  - Chronic infection
KW  - LCMV
KW  - autoimmune disease
KW  - dendritic cells
KW  - CXCR3
KW  - molecular mimicry
Y1  - 2006
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/50502
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-505027
SN  - 1740-2530
SN  - 1740-2522
N1  - Copyright © 2006 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
N1  - Der ursprüngliche Artikel wurde zurückgezogen. Er ist erschienen in: Clinical & developmental immunology, 13.2006, Nr. 1, S. 67-77, doi:10.1080/17402520600579028. Die Rücknahme ist erschienen in: Journal of Immunology Research, 2016, Art. 2747402, doi:10.1155/2016/2747402
VL  - 13
IS  - 2-4
SP  - 1
EP  - 11
PB  - Hindawi
CY  - New York, NY
ER  -